Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) has earned a consensus rating of “Buy” from the eight analysts that are presently covering the stock. Two analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $20.00.
Several equities analysts have weighed in on AMPH shares. BMO Capital Markets started coverage on Amphastar Pharmaceuticals in a report on Tuesday, June 28th. They set a “market perform” rating and a $17.00 target price on the stock. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a report on Monday, August 1st. Piper Jaffray Cos. restated an “overweight” rating and set a $23.00 target price (up from $22.00) on shares of Amphastar Pharmaceuticals in a report on Wednesday, September 7th. Jefferies Group raised their target price on Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Finally, Needham & Company LLC raised their target price on Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, August 9th.
In related news, President Jason B. Shandell sold 5,636 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $18.01, for a total transaction of $101,504.36. Following the sale, the president now directly owns 208,948 shares of the company’s stock, valued at $3,763,153.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Jason B. Shandell sold 56,996 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $19.50, for a total value of $1,111,422.00. Following the sale, the insider now directly owns 259,957 shares in the company, valued at $5,069,161.50. The disclosure for this sale can be found here. 29.30% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Amphastar Pharmaceuticals during the first quarter worth $180,000. Teachers Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 18.8% in the first quarter. Teachers Advisors Inc. now owns 492,136 shares of the company’s stock worth $5,906,000 after buying an additional 77,910 shares during the period. Menta Capital LLC purchased a new stake in Amphastar Pharmaceuticals during the first quarter worth $533,000. UBS Asset Management Americas Inc. increased its stake in Amphastar Pharmaceuticals by 10.0% in the first quarter. UBS Asset Management Americas Inc. now owns 277,294 shares of the company’s stock worth $3,328,000 after buying an additional 25,095 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Amphastar Pharmaceuticals by 81.0% in the second quarter. Acadian Asset Management LLC now owns 818,620 shares of the company’s stock worth $13,195,000 after buying an additional 366,249 shares during the period. 35.87% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals (NASDAQ:AMPH) traded up 1.001% on Monday, reaching $19.685. The company’s stock had a trading volume of 179,198 shares. Amphastar Pharmaceuticals has a 52 week low of $10.50 and a 52 week high of $21.53. The firm has a market capitalization of $888.21 million, a PE ratio of 63.912 and a beta of 1.83. The stock’s 50 day moving average is $19.31 and its 200-day moving average is $16.04.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Monday, August 8th. The company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.22. Amphastar Pharmaceuticals had a return on equity of 4.71% and a net margin of 5.19%. The company had revenue of $68 million for the quarter, compared to analyst estimates of $62.10 million. During the same period last year, the company earned ($0.09) earnings per share. The business’s revenue was up 26.4% compared to the same quarter last year. Analysts predict that Amphastar Pharmaceuticals will post $0.37 EPS for the current year.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.